Hold Biocon; target of Rs 375: ICICI Direct

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

ICICI Direct’s research report on Biocon
Biocon and Mylan are exclusive partners for biosimilar and insulin products. Trastuzumab is one of the six products co - developed by Biocon  and  Mylan for  global markets . Mylan has exclusive commercial rights for  the proposed biosimilar  Trastuzumab in the US, Canada, Japan, Australia,  New Zealand and Europe. Biocon has co - exclusive commercial rights with  Mylan in the rest of the world.

Outlook

We  have  assigned NPV value  for the US meant Trastuzumab after considering the market and other  dynamics . According ly , we arrive at  our new SOTP target price  of | 375 (from | 340 earlier). Given the recent  run - up in the stock , the  upside is  already  priced - in. Hence , we maintain our  HOLD recommendation.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More